Klotho is an early and sensitive marker for CKD
The expression level of klotho decreases in patients with #CKD (chronic kidney disease) and is accompanied by renal disorders.
In rodent models with CKD, #KLOTHO deficiency causes high circulating levels of phosphate and vascular calcification. Conversely, overexpression of klotho can enhance phosphaturia, improve renal function, and reduce calcification.
In CKD, KLOTHO levels start declining due to altered activin and ActRIIA signalling. This in turn limits KLOTHO’s regulation of FGF23 production and leaves #hyperphosphataemia as the principal regulator of FGF23 secretion in CKD.
Since KLOTHO levels change at an early stage of CKD, KLOTHO is a sensitive biomarker for the decline in kidney function.
To learn more about the mechanism of KLOTHO signalling check out https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-1094-z.
Learn more about our KLOTHO assay
- convenient (direct measurement, 10µl sample/well only)
- highly specific
- highly sensitive
- fully validated